Abstract
We found that an induction immunotherapy regimen consisting of rabbit anti-thymocyte globulin (Thymoglobulin) and the monoclonal antibody to CD20 rituximab (Rituxan) promoted long-term islet allograft survival in cynomolgus macaques maintained on rapamycin monotherapy. B lymphocyte reconstitution after rituximab-mediated depletion was characterized by a preponderance of immature and transitional cells, whose persistence was associated with long-term islet allograft survival. Development of donor-specific alloantibodies was abrogated only in the setting of continued rapamycin monotherapy.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antilymphocyte Serum
-
B-Lymphocyte Subsets / cytology
-
B-Lymphocyte Subsets / immunology*
-
B-Lymphocyte Subsets / metabolism
-
Cell Differentiation / immunology
-
Graft Survival / immunology*
-
Immunotherapy, Active* / methods
-
Islets of Langerhans Transplantation / immunology*
-
Lymphocyte Depletion
-
Macaca fascicularis
-
Rituximab
-
Transplantation, Homologous
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antilymphocyte Serum
-
Rituximab
-
thymoglobulin